Shanghai Junshi Biosciences Co., Ltd.

1877

CNE100003FF7

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
10.84 ^HKD	+0.93%		+17.32%	-44.24%

Apr. 25	Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	MT
Apr. 24	Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	CI

Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.

April 01, 2024

From January 1, 2024 to March 31, 2024, the company has repurchased 102,459 shares, representing 0.01% for CNY 3 million. With this, the company has completed the repurchase of 781,486 shares, representing 0.08% for CNY 29.88 million under the buyback announced on September 10, 2023.

Latest news about Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Receives Hong Kong Approval for Cancer Drug Toripalimab	Apr. 25	MT
Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region	Apr. 24	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Executive Changes	Apr. 24	CI
Junshi Biosciences Gets Nod to Register Toripalimab Injection	Apr. 08	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	Apr. 02	MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	Apr. 02	CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	Apr. 01	CI
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	Mar. 28	MT
Junshi Bio's 2023 Loss Widens, Misses Estimates	Feb. 25	MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Junshi Biosciences Proposes Share Buyback	Feb. 02	MT
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	Feb. 01	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	Feb. 01	CI
Shanghai Junshi Biosciences to Narrow Losses	Jan. 31	MT
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	Jan. 31	MT
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	Jan. 30	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer	Jan. 12	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Change of General Manager	Jan. 12	CI
Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board	Jan. 12	CI
Junshi Bio, Coherus Terminate Partnership for TIGIT Antibody	Jan. 11	MT
Shanghai Junshi Biosciences Co., Ltd. Receives Letter from Coherus Notifying the Company of its Intention to Terminate the Cooperation	Jan. 10	CI
Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine	Jan. 09	CI
Junshi Biosciences Secures Supplementary Application Approval for Lung Cancer Therapy in China	Jan. 03	MT
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	Jan. 02	CI

Chart Shanghai Junshi Biosciences Co., Ltd.

Duration

Period

Chart Shanghai Junshi Biosciences Co., Ltd.

More charts

Company Profile

Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases . The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-28 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Junshi Biosciences Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.942 CNY

Average target price

22.5 CNY

Spread / Average Target

+126.33%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.	-44.24%	3.18B
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.97%	39.82B
UCB	+56.59%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-13.65%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.82%	11.95B
INCYTE CORPORATION	-15.46%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-41.58%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.71B
INNOVENT BIOLOGICS, INC.	-7.02%	8.12B

Biopharmaceuticals

Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Pharmaceuticals

Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.

Latest news about Shanghai Junshi Biosciences Co., Ltd.

Chart Shanghai Junshi Biosciences Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Shanghai Junshi Biosciences Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals